FDA Rejection of Rare Disease Drug Sparks Debate on Approval Pathways
Stealth BioTherapeutics' drug for Barth syndrome, a rare illness affecting up to 150 people in the U.S., was unexpectedly rejected by the FDA, delaying access for patients and straining the company's finances, despite prior advisory committee support and ongoing discussions about new approval pathways.